AbbVie Inc. ABBV reported second-quarter 2025 adjusted EPS of $2.97, which beat the Zacks Consensus Estimate of $2.89. The reported figure also exceeded the company’s guidance of $2.84-$2.88 issued ...
AbbVie Inc. ABBV reported third-quarter 2025 adjusted EPS of $1.86, which beat the Zacks Consensus Estimate of $1.77. The reported figure also exceeded the company’s guidance of $1.74-$1.78 issued ...
Roche Holding’s (OTCMKTS:RHHBY) revenue grew at a CAGR of 5.3% from $52.5 billion in 2015 to $64.4 billion in 2019, and it is estimated to top $66 billion in 2020, led by its Neuroscience drugs. The ...
AbbVie ABBV holds a leadership position in the neuroscience space, which encompasses blockbuster medications such as Botox Therapeutic and depression drug Vraylar. Over the years, the company has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback